Efficacy, safety, and feasibility of youth-derived fecal microbiota transplantation among adults with type 1 diabetes mellitus: A protocol of Pilot Randomized Controlled Trial
Open Access
- 21 September 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0343078
Abstract
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This pilot trial aims to assess the feasibility, safety, and preliminary efficacy of yFMT in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin [HbA1c] of 7.0–14.0% or time in range [TIR] 70% and time below range <4% at 12 weeks post-randomization. Secondary efficacy endpoints include: (1) the change from baseline in the same composite achievement rate at 4 weeks post-intervention; (2) changes from baseline at Weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting plasma glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition; and (3) changes from baseline at Week 12 in serum metabolomic profiles (bile acids, short-chain fatty acids, and other related metabolites). Feasibility will be assessed through recruitment rate, retention rate, intervention adherence, and acceptability. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT capsules in adults with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome‑based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).Keywords
Funding Information
- the national key Research and Development Program of China (2024YFC3505100)
This publication has 21 references indexed in Scilit:
- Restoration of intestinal secondary bile acid synthesis: A potential approach to improve pancreatic β cell function in type 1 diabetesCell Reports Medicine, 2025
- Effects of clinical donor characteristics on the success of faecal microbiota transplantation for patients in Denmark with Clostridioides difficile infection: a single-centre, prospective cohort studyThe Lancet Microbe, 2025
- Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trialeClinicalMedicine, 2024
- Gut microbiota modulate distal symmetric polyneuropathy in patients with diabetesCell Metabolism, 2023
- Glycaemic control and its associated factors in Chinese adults with type 1 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2015
- Aberrant gut microbiota composition at the onset of type 1 diabetes in young childrenDiabetologia, 2014
- Secondary diabetic ketoacidosis and severe hypoglycaemia in patients with established type 1 diabetes mellitus in China: a multicentre registration studyDiabetes/Metabolism Research and Reviews, 2014
- Human gut microbiome viewed across age and geographyNature, 2012
- Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouseDiabetologia, 2005
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998